• Improving retention in care in the first year after HIV diagnosis is critical to optimize patient health outcomes; few interventions specifically designed to retain patients in the early stages of HIV care have been tested.
• This article outlines a randomised controlled trial protocol to determine the effectiveness and cost-effectiveness of a text-messaging intervention (WelTel) to retain patients in HIV care in the first year after diagnosis.
Key messages
• The WelTel intervention has been found effective at promoting adherence among HIV patients taking antiretroviral therapy; this trial will determine whether the intervention is also effective in earlier stages along the continuum of HIV care.
• Mobile health interventions need to be evidence-based and rigorously tested before they are considered for implementation and scale-up.
Strengths and limitations of this study
• The trial has a tracing component to ascertain the true outcome of participants initially deemed 'lost-to-follow-up', leading to a more accurate assessment of retention in care.
• The primary limitation is that WelTel Retain is a single-site study in a resourcelimited setting; generalizability to other settings may be limited. 
Methods and analysis: WelTel
Retain is an open, parallel group RCT that will be conducted at the Kibera Community Health Centre in Nairobi, Kenya. Over one year, we aim to recruit 686 individuals newly diagnosed with HIV who will be randomly allocated to an intervention or control arm (standard care) at a 1:1 ratio. Intervention arm participants will receive the weekly WelTel SMS "check-in" to which they will be instructed to respond within 48 hours. An HIV clinician will follow-up and triage any problems that are identified. Participants will be followed for one year, with a primary endpoint of retention in care at 12 months. Secondary outcomes include retention in Stage 1 HIV care (patients return to the clinic to receive their first CD4 results) and timely ART initiation. Costeffectiveness will be analysed through decision-analytic modelling. 
Ethics and dissemination:

INTRODUCTION
As HIV care and treatment programs in resource-limited settings move away from emergency delivery of care to long-term management, patient retention in care is increasingly recognized as critical to the success of these programs. Along the cascade of care (figure 1), from diagnosis to clinical evaluation and readiness for antiretroviral therapy (ART), through to long-term follow-up, high rates of attrition from care occur at several intervals. Between diagnosis and initiation of ART, fewer than two-thirds of patients remain continuously in care. 1 In Kenya, a study at a large HIV care centre estimated 12-month clinic retention among ART-ineligible patients at 63%; after introducing the provision of free co-trimoxazole to pre-ART patients, 12-month retention increased to over 80%. 2 Consequences of attrition include an increased risk of morbidity, mortality and a greater strain on limited healthcare resources (resulting from patients returning to care when they are seriously ill). [3] [4] Conversely, retaining patients in care before they start HIV treatment facilitates the timely initiation of ART, and the provision opportunistic infection prophylactic medication and prevention of mother-to-child transmission (PMTCT) services. The global expansion in mobile phone use, with high rates of uptake in Africa, presents new opportunities to incorporate the use of cell phones into health service delivery to help engage patients in care. In 2012, the cell phone penetration rate (number of subscribers as a proportion of the population) in Kenya was 77%, with continued growth in the use of short message service (SMS). 5 Shared phone use is common in the region and further increases the proportion of Kenyans who use a mobile phone. 6 The WelTel Kenya1 study sought to capitalize on this expansion in mobile phone access to improve health care delivery, and through a multi-site randomized controlled trial (RCT), demonstrated that the WelTel text-messaging intervention is effective in improving adherence to medication and viral load suppression in HIV-infected individuals who had initiated ART. 7 Narrative reports from participants explained that communication with their providers allowed them to feel connected with the healthcare system. It is unknown; however, whether the WelTel intervention can help prevent attrition across the cascade of care. This study will examine the effectiveness, and cost-effectiveness, of the WelTel mobile health (mHealth) intervention to improve retention in care in the early stages of HIV care in Kenya.
Research hypothesis
The WelTel patient-centered SMS service is a cost-effective strategy to improve patient retention in care in the first year following HIV diagnosis.
Study objectives
Primary objective
To determine the effect of the WelTel intervention compared to standard care on 12-month retention in care in patients newly diagnosed with HIV. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 • Evaluate the cost-effectiveness of the WelTel intervention on patient retention in care over one year. Employ lifetime decision analytic modelling to describe the benefit on lifetime clinical and economic outcomes of additional patients retained in care.
Key secondary objectives
Other secondary objectives
• Determine the effect of the intervention on 6-month retention in care, level of engagement in care, timely initiation of ART, social support and satisfaction with care.
• Determine whether the effect of the WelTel intervention differs among important subgroups (sex, age, phone ownership, distance from clinic, and baseline ARTeligibility status).
METHODS AND ANALYSIS
Trial design
WelTel Retain is a single site, two-arm, open, randomised, parallel-group study with a 1:1 allocation ratio.
Study setting
The trial will take place at the Kibera Community Health Centre, an African Medical and
Research Foundation (AMREF) clinic in Nairobi, Kenya, which serves over 4,000 HIVinfected individuals. The health centre is a comprehensive care clinic, and there are no direct patient costs for HIV/AIDS care and treatment. The clinic is located in the heart of Kibera, one of the largest informal settlements in Africa, with an ethnically diverse population of approximately 170,000. 8 The population the clinic serves lacks or has 
Study population
The study population consists of adults aged 18 or over who test positive for HIV at the Kibera Community Health Centre and have not been previously assessed for ART eligibility. Individuals who test positive for HIV based on two rapid HIV tests will be referred to a research nurse. The research nurse will complete an eligibility checklist:
individuals must fulfil all inclusion criteria and none of the exclusion criteria to participate.
Inclusion criteria:
• adult (18 years of age or older)
• have an HIV test at the Kibera Community Health Centre
• evidence of HIV infection
• own or have sufficient access to a cell phone
• able to operate a cell phone using simple text-messaging, or have a partner, relative, etc., respond on their behalf
• able and willing to provide informed consent to participate Exclusion criteria:
• previous ART exposure
• currently taking ART
• previously assessed for ART eligibility 
Interventions
Participants will be randomly assigned to receive the WelTel text-messaging service or to usual care. The WelTel intervention involves a weekly short message service (SMS) to check-in on how patients are doing and provide them the opportunity to identify whether assistance is required ( figure 2 ). For example, on Monday mornings, an automated text message from a central computer platform at the clinic will be sent to intervention arm participants asking "Mambo?" (Kiswahili for "How are you?"). Participants will be instructed to indicate within 48 hours of receiving the message either that they are well (e.g.
"OK" or "Sawa") or that they have a problem (e.g. "Problem" or "Shida"). A nurse experienced in HIV care will follow-up all participants who identify a problem. Those who do not respond after 48 hours will be called by the nurse to inquire as to their status.
Participants will be informed that the SMS support service supplements, but does not replace, existing counseling or clinical services and that all emergencies should be handled by usual means. All cell phone communication resulting from the SMS queries will 
Outcomes
Primary outcome
The primary outcome is 12-month retention in care: defined as the proportion of participants retained in care at 12-months from baseline, measured as whether the participant attended a follow-up appointment in the 10 to 14 month time frame.
Key secondary outcome
Retention in Stage 1 HIV care: defined as the proportion of participants who return to the clinic to complete their first ART eligibility assessment after receiving a positive HIV test. 10 Additional secondary outcomes
• The proportion of participants who are ART-eligible at baseline who initiate ART within three months of HIV diagnosis.
• Time to ART initiation (for those who are ART-eligible at baseline)
• 6-month retention in care (attendance at a 6-month appointment within the 5-7 month timeframe) • Level of social support (adapted Medical Outcomes Study Social Support Survey) 11 • Satisfaction with care
• Adverse events (number and grade)
• Mortality (all-cause)
A summary of primary and secondary outcomes and related hypotheses is presented in For those initially deemed ART-ineligible, Stage 2 HIV care is the time from completing the first ART eligibility assessment to ART eligibility, while Stage 3 is the period from when a patient learns of their ART eligibility to ART initiation. 10 We will recruit participants at the time of their first positive HIV test, at which point the intervention is randomly allocated; therefore, we are precluded from measuring whether the intervention has an effect on retention in Stage 2 or 3 of pre-ART HIV care i.e. because participants' baseline does not coincide with the start of the time period for later stages of pre-ART HIV care. For our primary outcome, 12-month retention in care, we will use a timeframe of 10-14 months will be used in order to accommodate differing visit schedules, which vary according to whether patients are taking ART, how recently they have started treatment (ART or co-trimoxazole), and how adherent they are to medication (ART or cotrimoxazole). Since our primary endpoint involves attendance at one appointment only, to better capture patient engagement in care we have included secondary outcomes to measure the effect of the intervention on engagement throughout the 12-month period (table 2) .
With retention in care as the primary trial outcome, it is important distinguish between retention in care and retention in clinic. This is particularly relevant given the decentralization and expansion of HIV care in the area. As patients have increasing options as to where they seek their care, a lack of retention in clinic is not necessarily equivalent to a lack of retention in care. A review by Geng et al suggests that retention in clinic is a poor proxy for retention in care, 12 and studies have revealed significant differences in estimates of patients retained in care when a concerted effort has been made to trace those initially 13 We have taken a patient perspective in our definition of retention in care, with retention defined as patients who remain in care at 12-months, even if they are accessing care outside the Kibera Community Health Centre. To determine whether participants have been retained in care, we will actively trace participants deemed "lost to follow up" in both the intervention and control groups after participants have reached the end of the follow-up period. A trained health care worker knowledgeable in the community setting will trace participants, who will have given their consent during the enrolment process. The tracing aspect of the trial will enable us to ascertain the participants' true status (death, transfer of care, or lost to care). Transferred patients active in care will be considered retained.
Sample size
Based on a 1:1 allocation ratio, an alpha of 0.05 (two-sided) and 80% power, it is estimated that we require 343 participants in each study arm. This calculation is based on finding a significant difference between the intervention and control arms in the primary outcome:
the proportion of retained versus non-retained participants at 12 months. Sample size was calculated using the IcebergSim software version beta 4.0.3 (Practihc Coordinating Office, Oslo, Norway), a clinical trial simulator using a Monte Carlo model with 5,000 simulations. Our estimate assumes 12-month retention in 65% of control arm participants (K Kinagwi, personal communication, 2011) and a conservative estimate of 75% of patients retained at 12-months in the intervention group. This difference was selected as the smallest difference that would be important to detect and is assumed to be reasonable in the sense that an effect of this magnitude might be anticipated in this field of research. 
Recruitment
Clinic staff will identify potential participants at the time of HIV diagnosis and inform them about the study (figure 3). If an individual expresses interest in the study, the clinic staff will introduce them to the research nurse who will explain the trial in further detail.
The research nurse will use a checklist to assess eligibility; eligible individuals will be invited to participate and informed consent will be sought. The research nurse will maintain a recruitment log to document screened patients and will report the number of participants recruited on a weekly basis. We expect to enrol 686 participants over a oneyear period. Participants will receive 150 Kenyan Shillings (KES) at the baseline visit (enrolment) and 150 KES for each subsequent study visit (6-and 12-months) to reimburse them for their time. They will not be reimbursed for costs associated with responding to the weekly messages. Participants will be informed through the consent process that they may withdraw from the study at any time for any reason without it affecting their medical care.
Randomization and allocation
Randomization of participants to the intervention or control arm will be at a 1:1 ratio, using a computer-generated randomization list. To achieve balance between the treatment arms during the trial, blocked randomization will be used, with random sequences of different block sizes. The block sizes will not be disclosed, to ensure concealment.
Allocations have been computer generated using the ralloc procedure 14 in Stata 12.0 (Stata Corporation, College Station, Texas, USA). The individual responsible for sequence generation and allocation concealment will not be involved in the implementation of treatment assignments. Written allocation of assignment will be sealed in individual, sequentially numbered, non-resealable, opaque envelopes that will be distributed to the clinic in sufficient quantity to allocate the target number of participants. After meeting inclusion criteria, consenting to participate, and completing baseline assessments, participants will be immediately assigned to the randomized study arm by the research nurse who will open one of the sequentially numbered envelopes to determine allocation. Before opening the envelope, the participant's details will be written on the envelope. The assignment schedule will be kept off-site in a locked filing cabinet at the University of Nairobi.
Blinding
Participating clinic staff and participants cannot be blinded because the intervention requires overt participation; however, the data analyst will be blinded.
Follow-up
Follow-up visits will occur as per routine clinical practice; each visit will be recorded.
For all patients who test HIV positive, a visit is scheduled in two weeks to receive CD4 test results. For ART-ineligible patients, if they are adherent to co-trimoxazole and do not experience side effects, they are usually followed up once a month for the first six months. If patients remain adherent after six months, visits are scheduled every two months. ART-eligible patients are initially followed-up monthly; however, the interval between visits may increase to up to three months. In both the intervention and control groups, study procedures will occur at the 6 and 12-month clinical visits, during which the research nurse will administer a follow-up questionnaire. The locator form will be updated; and clinical and laboratory data retrieved. The final follow-up visit will be the 
Data collection and management
WelTel's technological platform will capture the outgoing weekly SMS messages and incoming participant responses and instances of non-response. The research nurse will use the platform to record reasons why a participant responded with a problem or did not respond, and actions taken. Data captured by the platform will be backed up on a daily basis.
Questionnaire and other study-related data will be paper-based and entered into a Microsoft Access database at the clinic site by the data manager. Questionnaires were developed using validated measures where possible. They were translated into Kiswahili and then back-translated to English. The questionnaire is in both languages. After translation, the questionnaire was pilot tested during staff training and with patients. The data manager will check all forms for completeness. Data processing will include range and consistency checks. Any queries will be resolved promptly. Data quality will be verified by re-checking a random sample of 10% of data collected. Participant files will be stored in a locked office at the trial site.
Statistical methods
Descriptive statistics of participants' baseline characteristics will be presented to assess their comparability. These statistics will be reported as a mean (standard deviation [SD]) or median (first quartile, third quartile) for continuous variables, and count (percent) for For the primary analysis, we will compare the proportion of participants retained at 12-months in the SMS group to the control group using a Chi-square test (table 1) . Our analysis will be intention-to-treat; therefore, we will include all randomized patients according to the study group to which they were originally allocated regardless of subsequent intervention received. Results will be reported as the number of participants (with percentages) for each treatment group, the relative risk (RR) with 95% confidence intervals (CI) and p-values. We will also calculate the number needed to treat (NNT) for the primary outcome. Secondary binary outcomes will be similarly analyzed. For other types of secondary outcomes, we will because of potential heterogeneity in the risk of loss to care without an intervention (with males, those who are at a greater distance from clinic, and those ineligible for ART more likely to be lost to care) 12 and potential variance in the effect of the intervention resulting from underlying differences between groups of patients in adopting a cell phone intervention (sex, age, and phone ownership). We will assess whether the intervention effect is homogeneous across these subgroups by including an interaction term between the intervention allocation and subgroup-defining variables in the model. P-values for the interaction tests, rather than the treatment effect within groups, will be reported. We will report all subgroup results, regardless of significance.
Missing data will be handled using multiple imputation methods. 15 The criterion for statistical significance will be set at alpha=0.05. The results will be reported as estimate of the effect, corresponding 95% confidence interval and associated p-values. All p-values will be reported to three decimal places with those less than 0.001 reported as p<0.001.The data will be analyzed with up-to-date versions of Stata statistical software (Stata Corporation, College Station, Texas, USA).
Data monitoring, interim analysis and stopping guidelines
A Data and Safety Monitoring Board (DSMB), independent of the study sponsor and investigators, has been established for the trial. The board comprises a clinic trials specialist who is the Chair, a biostatistician, and an expert in HIV clinical care and trials in Kenya.
The DSMB will periodically review safety and efficacy data. A single interim analysis will be conducted when half of the patients have reached the scheduled time of their 12-month follow-up visit. The DSMB will use the Hayebittle-Peto rule, with a conservative p-value of <0.001, as a guideline to recommend that the trial be stopped. [16] [17] This enables us to maintain an alpha error of 0.05 for the final analysis. Recommendations for termination of the trial will be considered if there are differences in favour of one group or the other. All adverse events occurring after enrolment until study exit (12-months follow-up for retained participants and until the end of the tracing aspect of the study for those not retained in clinic) will be recorded. Adverse events include those directly attributable to the intervention, such as accidental disclosure of HIV status, and those resulting from participation in the trial. Potential harms will be outlined during the informed consent process and potential participants will be notified as to whom these events should be
Harms
reported. An adverse event report form based on standard forms of the relevant institutional review boards (IRB) will be used as a reporting tool. The research nurse will document adverse events in a weekly study log and during follow-up visits with participants. Before the start of the trial, health care staff will undergo training with respect to the recognition and reporting of adverse events. The DSMB will have access to the study data to review the occurrence of such events. Descriptive statistics will be used to report adverse events.
All unanticipated problems involving risks to human participants or others will be reported to the supporting Health & Human Services (HHS) agency head (or designee), the Office for Human Research Protections (OHRP), research sponsor, and the IRBs.
Unanticipated problems will be defined by OHRP criteria, as outlined in documentation on 'Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events'. 18 Adverse events and unanticipated problems will be promptly reported to the appropriate officials in accordance with OHRP recommendations and IRB regulations. Unanticipated problems will be reported to the IRBs within two weeks of the investigator becoming aware of the problem, unless the unanticipated problem is serious, in which case problems will be reported within one week.
Unanticipated problems will be reported to the research sponsor, supporting agency head 
Qualitative aspects
Formative and post-trial qualitative studies involving patients and healthcare workers from the study site will be conducted. The purpose of the formative phase is to gain an understanding of potential barriers and patient knowledge of retention in care generally, and to inform any necessary adaptation of the WelTel intervention. Semi-structured interviews will be conducted with five healthcare workers and 15 patients, recruited through convenience sampling. Eligibility criterion for healthcare workers is employment at the Kibera Community Health Centre (KCHC). Patients will be eligible if they are a KCHC client, ≥18 years, HIV positive, and willing to provide consent. Interviews will be conducted in English with a translator fluent in Kiswahili and English present to assist. The interviews will be recorded, translated into English (if needed), and transcribed verbatim.
Data will be analyzed using an inductive thematic approach. Two researchers will read interview transcripts numerous times to identify important concepts, events and experiences. 19 Once a consistent coding framework is established, transcripts will be coded using NVivo 9 (QSR International Pty Ltd, Doncaster, Australia) software. To increase reliability, 20% of transcripts will be double coded.
The follow-up qualitative study will be conducted after the trial is complete, the purposes of which are to gain an understanding of participants' experiences during the first year of HIV care, specifically as they relate to retention, and with the WelTel intervention.
Theoretical sampling will be used to identify potential participant groups for recruitment.
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For example, we may recruit individuals who were initially deemed lost to follow-up but in order to gain a range of perspectives. We will recruit patients who participated in the trial and healthcare providers involved in the trial until data saturation is achieved.
Cost-effectiveness evaluation
Decision analytic modeling will be used to assess WelTel from a health care payer/donor
perspective. An incremental analysis will evaluate the intervention compared to standard care. Direct costs of text messaging, infrastructure maintenance and technical support will be collected through trial reports and electronic reports generated by the WelTel platform.
Estimates of labour costs will be derived using the activity based costing method. 20 The WHO-CHOICE database will be utilized to price labour and other resources used.
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Participant questionnaire data will include patient-specific costs and time missed from work that will be used in a secondary societal analysis.
Relative risk of loss to care within one year of diagnosis will describe the benefit of WelTel compared to standard care over a short time horizon. Modeling will extend the time horizon to life-long due to the chronic nature of HIV disease. The model will be populated using parameters identified from the literature such as rates of transmission, opportunistic infection and complications. Incremental improvements in retention will be transformed into disability-adjusted life-years (DALY) averted.
We will report the incremental cost-effectiveness ratio (ICER), in this case the ratio of the incremental cost to provide WelTel over usual care and the effect of DALY averted.
The summary measure will be the incremental cost per patient retained over one year. The ICER will also be determined for cost per DALY averted, so that we may compare WelTel to other global health strategies and programs. 21 In accordance with WHO guidelines, we 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   23 will use a discount rate of 3%. 21 Probabilistic sensitivity analyses will be conducted on the discount rate, retention rates, costs of WelTel, costs of resources such as ART and other pertinent variables. We will perform scenario analyses including lifetime projections assuming consistent effects of WelTel over time, diminishing effects, and no effect beyond one year. Consistent with WHO-CHOICE standards, the threshold for cost-effectiveness is three times per capita gross domestic product (GDP) per DALY averted. 21 A very costeffective intervention is less than one times GDP per DALY averted. 21 These thresholds will be shown on an incremental cost-effectiveness plane that will be constructed from the probabilistic analysis.
Ancillary studies
Participant engagement with the WelTel intervention
To better understand participant engagement with the intervention, a detailed descriptive analysis of cell phone communication will be conducted. This will include a summary of problems identified through the intervention and reasons why patients did not respond to the messages. Factors associated with responding with a problem and non-response will also be examined. Several mobile health (mHealth) interventions have experienced significant declines in participant response rates over time, [22] [23] [24] bringing into question the long-term sustainability of these interventions. Response rates remained stable during the 12-month study period of the WelTel Kenya1 trial, 25 this trial will confirm whether response rates to the WelTel service are equally durable in among patients in an earlier stage of HIV care. Patient-perceived benefits of and barriers to the intervention will also be examined.
2. Retention during the first year of HIV care and factors associated with loss to care In their systematic review, Rosen and Fox indicate that studies adequately quantifying loss to care are scarce. 1 To this end, we will conduct a prospective cohort study alongside the RCT to evaluate participant retention in the early stages of HIV care. Participants involved in the trial will be included in the cohort. To increase the generalizability of study findings, in addition to trial participants, patients ineligible for the trial, e.g. because they do not have cell phone access, will also be eligible to participate in the cohort study. Participants will be followed-up for 12-months. Objectives of the cohort study are to quantify loss to care in the first year after diagnosis and to determine risk factors associated with loss to care.
ETHICS AND DISSEMINATION
Research ethics approval
The original study protocol, information and consent form, and baseline questionnaire were 
Consent
After a clinic staff member introduces the trial, a trained research nurse will provide the potential participant with further details. If the participant would like to enrol, the research nurse will discuss the information in the consent form with them in the language in which the potential participant is most comfortable, English or Kiswahili. Participants will be given the opportunity to ask questions before providing written consent. Once signed, each participant will be provided with a copy of the information and consent form. Illiterate 
Confidentiality
To maintain participant confidentiality, all personally identifying information will be removed from questionnaires and study documents where possible. Participants will be identified on these forms by a unique study identification number (ID). Study documents containing personal information e.g. locator form, informed consent forms, etc. will be kept off-site and separate from other study data. Completed questionnaires and study documents will be stored in locked filing cabinets with limited access. All personally identifying information will be removed from interview transcriptions. The risk of breach of confidentiality resulting from the text messaging intervention will be minimized since the content of the text message will not include language related to HIV. Data stored on computer databases will be password-protected and access to files will be limited.
Dissemination
Regardless of the significance, direction or magnitude of effect, we will publish our primary findings and ancillary studies in peer-reviewed journals. We will also report study findings through conference abstracts, relevant websites, at workshops and to the participating clinic staff and patients. Once all of the data has been collected and cleaned, we will aim to submit the trial results for publication within three months.
CONCLUSION
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